Факторы риска развития остеопороза у больных ревматоидным артритом
https://doi.org/10.14412/1995-4484-2014-562-571
Аннотация
Данный обзор посвящен рассмотрению факторов риска (ФР) развития остеопороза (ОП) у больных ревматоидным артритом (РА) – как связанных с основным заболеванием, так и не связанных. Предполагается, что наиболее значимыми предикторами снижения минеральной плотности кости являются тяжелое течение РА, выраженная функциональная недостаточность по HAQ, терапия глюкокортикоидами, пожилой возраст, недостаточная масса тела или низкий индекс массы тела, наличие менопаузы. Однако, несмотря на большое количество проведенных исследований, результаты по ФР ОП остаются противоречивыми и требуют дальнейшего изучения.
Об авторах
Е. А. Таскина
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия
Россия
Россия
Л. И. Алексеева
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия
Россия
Россия
Список литературы
1. Насонова ВА, Сигидин ЯА. Патогенетическая терапия ревматических заболеваний. Москва: Медицина; 1985;47–58, 146–58. [Nasonova VA, Sigidin YaA. Patogeneticheskaya terapiya revmaticheskikh zabolevanii [Pathogenetic therapy of rheumatic diseases]. Moscow: Meditsina; 1985;47–58, 146–58.]
2. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматология. Национальное руководство. Под ред. Е.Л Насонова, В.А Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-media; 2008. P. 290–331.]
3. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Amer.2001;27:269–81.
4. Vallbracht I, Rieber J, Oppermann M, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004;63:1079–84. DOI: 10.1136/ard.2003.019877.
5. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(3):265–72. DOI: 10.1186/ar578.
6. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 2003;48(4):917–26. DOI: http://dx.doi.org/10.1002/art.10897.
7. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522–30. DOI: http://dx.doi.org/10.1002/1529- 0131(200003)43:3%3C522::AID-ANR7%3E3.0.CO;2-Y.
8. Гукасян ДА, Насонов ЕЛ, Балабанова РМ, Смирнов АВ. Минеральная плотность костной ткани у больных ревматоидным артритом. Клиническая медицина. 2001;(12):68–70. [Gukasyan DA, Nasonov EL, Balabanova RM, Smirnov AV. The mineral density of a bone tissue at patients with rheumatoid arthritis. Klinicheskaya meditsina. 2001;(12):68–70. (In Russ.)]
9. Насонов ЕЛ, Скрипникова ИА, Насонова ВА. Проблема остеопороза в ревматологии. Москва: Стин; 1997. 429 с. [Nasonov EL, Skripnikova IA, Nasonova VA. Problema osteoporoza v revmatologii [Osteoporosis problem in rheumatology]. Moscow: Stin; 1997. 429 p.]
10. _rstavik RE, Haugeberg G, Uhlig T, et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis. 2004;63(2):177–82. DOI: 10.1136/ard.2003.005850.
11. Orstavik RE, Haugeberg G, Mowinckel P, et al.Vertebral deformities in rheumatoid arthritis: a comparison with populationbased controls. Arch Intern Med. 2004;164(4):420–5. DOI: http://dx.doi.org/10.1001/archinte.164.4.420.
12. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;344:23–7. DOI:10.1016/S0140-6736(94)91049-9.
13. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis.1977;36(1):71–3. DOI: http://dx.doi.org/10.1136/ard.36.1.71.
14. Shimizu S, Shiozawa S, Shiozawa K, et al. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum.1985;28:25–31. DOI: http://dx.doi.org/10.1002/art.1780280105.
15. Kroger H, Arnala I, Rehnberg V, et al. Histomorphometry of periarticular bone in rheumatoid arthritis. Ann Chir Gynaecol. 1994;83:56–62.
16. Sambrook PN, Ansell BM, Foster S, et al. Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies. Ann Rheum Dis. 1985;44(9):580–4. DOI: http://dx.doi.org/10.1136/ard.44.9.580.
17. Deodar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a rewiew. Br J Rheumatol. 1996;35:309–22. DOI: http://dx.doi.org/10.1093/rheumatology/ 35.4.309.
18. Westhovens R, Dequeker J. Rheumatoid arthritis and osteoporosis. Z Rheumatol. 2000;59(1):33–8. DOI: http://dx.doi.org/10.1007/s003930070036.
19. Green MJ, Deodhar AA. Bone changes in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15:105–23. DOI: http://dx.doi.org/10.1053/berh.2000.0129.
20. Burger H, de Laet CE, van Daele PL, et al. Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol. 1998;147:871–9. DOI: http://dx.doi.org/10.1093/oxfordjournals.aje.a009541.
21. Gü ler-Yü ksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67:823–8. DOI: 10.1136/ard.2007. 073817.
22. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: A longitudinal study. Clin Exp Rheumatol. 2000;18:683–90.
23. Shenstone BD, Mahmoud A, Woodward R, et al. Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol. 1994;33:541–5. DOI: http://dx.doi.org/10.1093/rheumatology/33.6.541.
24. Haugeberg G, Orstavik RE, Uhlig T, et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum. 2002;46:1720–8. DOI: http://dx.doi.org/10.1002/art.10408.
25. Kroot EJ, Nieuwenhuizen MG, Waal Malefijt MC, et al. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum. 2001;44:1254–60. DOI: http://dx.doi.org/10.1002/1529-0131(200106)44:6%3C1254::AID-ART216%3E3.0.CO;2-G.
26. Aman S, Hakala M, Silvennoinen J, et al. Low incicidence of osteoporosis in a Two Year Follow-up of Early Community Based Patients with Rheumatoid Arthritis. Scand J Rheumatol. 1998;27:188–93. DOI: http://dx.doi.org/10.1080/030097498440796.
27. Kvien TK, Haugeberg G, Uhlig T, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000;59;805–11. DOI: http://dx.doi.org/10.1136/ard.59.10.805.
28. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59:110–5. DOI: 10.1136/ard.59.2.110.
29. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27(11):2582–9.
30. Nolla JM, Fiter J, Gomez-Vaquero C, et al. Value of clinical factors in selecting postmenopausal women with rheumatoid arthritis for bone densitometry. Ann Rheum Dis. 2001;60:799–801. DOI:10.1136/ard. 60.8.799.
31. Haugeberg G, Orstavik RE, Uhlig T, et al. Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis. 2002;61:1085–9. DOI: http://dx.doi.org/10.1136/ard.61.12.1085.
32. Savickiene A, Baranauskaite A. Changes in bone mineral density in rheumatoid arthritis. Medicina (Kaunas). 2002;38(2):190–6.
33. Forsblad D'Elia H, Larsen A, Waltbrand E, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis. 2003;62:617–23. DOI: 10.1136/ard.62.7.617.
34. Lodder MC, Haugeberg G, Lems WF, et al. Radiographic Damage Associated With Low Bone Mineral Density and Vertebral Deformities in Rheumatoid Arthritis: The Oslo-Truro- Amsterdam (OSTRA) Collaborative Study. Arthritis Rheum. 2003;49(2):209–15. DOI: 10.1002/art.10996.
35. De Jong Z, Munneke M, Lems WF, et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum. 2004;50(4):1066–76. DOI: 10.1002/art.20117.
36. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis. 2004;63:1576–80. DOI: http://dx.doi.org/10.1136/ard.2003.016253.
37. Di Munno O, Mazzantini M, Sinigaglia L, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol. 2004;31(7):1305–9.
38. Kaz Kaz H, Johnson D, Kerry S, et al. Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. Rheumatology (Oxford). 2004;43(10):1267–71. DOI: http://dx.doi.org/10.1093/rheumatology/keh304.
39. Hämä lä inen H, Kautiainen H, Kaarela K, Kotaniemi A. The development of bone mineral density and the occurrence of osteoporosis from 15 to 20 years of disease onset in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(2):193–8.
40. Silva RG, Pippa MG, Zerbini CA. Evaluation of body composition and bone mineral density in women with rheumatoid arthritis. Rev Assoc Med Bras. 2007;53(2):135–41. DOI: http://dx.doi.org/10.1590/S0104-42302007000200018.
41. Mazzantini M, Di Munno O, Sinigaglia L, et al. Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study. Clin Exp Rheumatol. 2007;25(5):709–15.
42. Gü ler-Yü ksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis. 2007;66(11):1508–12. DOI: 10.1136/ard.2007.070839.
43. Book C, Karlsson M, Akesson K, Jacobsson L. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol. 2008;37(4):248–54. DOI: http://dx.doi.org/10.1080/03009740801998747.
44. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68(3):373–6. DOI: 10.1136/ard.2008.091611.
45. Solomon DH, Finkelstein JS, Shadick N, et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1624–31. DOI: 10.1002/art.24551.
46. Heberlein I, Demary W, Bloching H, et al. Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study). Z Rheumatol. 2011;70(9):793–8, 800–2. DOI: 10.1007/s00393-011-0872-9.
47. Ghazi M, Kolta S, Briot K, et al. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23(2):581–7. DOI:10.1007/s00198-011-1584-3.
48. Mobini M, Kashi Z, Ghobadifar A. Prevalence and associated factors of osteoporosis in female patients with rheumatoid arthritis. Caspian J Intern Med. 2012;3(3):447–50.
49. Hafez EA, Mansour HE, Hamza SH, et al. Mineral density changes in patients with recent-onset rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2011;4:87–94. DOI: 10.4137/CMAMD.S7773.
50. Coulson KA, Reed G, Gilliam BE, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15(4):155–60. DOI: 10.1097/RHU.0b013e3181a5679d.
51. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–53. DOI: http://dx.doi.org/10.1002/art.1780261107.
52. Sugiguchi S, Goto H, Inaba M, Nishizawa Y. Preferential reduction of bone mineral density at the femur reflects impairment of physical activity in patients with low-activity rheumatoid arthritis. Mod Rheumatol. 2010;20(1):69–73. DOI: 10.1007/s10165-009-0242-5.
53. Sarkis KS, Salvador MB, Pinheiro MM, et al. Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study. Sao Paulo Med J. 2009;127(4):216–22. DOI: http://dx.doi.org/10.1590/S1516-31802009000400007.
54. Curtis JR, Arora T, Donaldson M, et al. Skeletal health among african americans with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61(10):1379–86. DOI: 10.1002/art.24841.
55. Krö ger H, Honkanen R, Saarikoski S, Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-a population based study. Ann Rheum Dis. 1994;53(1):18–23. DOI: http://dx.doi.org/10.1136/ard.53.1.18.
56. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA, et al. Circulating leptin and bone mineral density in rheumatoid arthritis. J Rheumatol. 2009;36(3):512–6. DOI: 10.3899/jrheum.080196.
57. Keller C, Hafströ m I, Svensson B; BARFOT study group. Bone mineral density in women and men with early rheumatoid arthritis. Scand J Rheumatol. 2001;30(4):213–20. DOI: http://dx.doi.org/10.1080/030097401316909558.
58. Shibuya K, Hagino H, Morio Y, Teshima R. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol. 2002;21(2):150–8. DOI: http://dx.doi.org/10.1007/s10067-002-8274-7.
59. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11. DOI: http://dx.doi.org/10.1016/S0140-6736(01)06075-5.
60. Sambrook PN. The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? J Rheumatol. 2000;27:2541–2.
61. Forslind K, Keller C, Svensson B, Hafströ m I; BARFOT Study Group. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol. 2003;30(12):2590–6.
62. Tourinho TF, Stein A, Castro JA, Brenol JC. Rheumatoid arthritis: evidence for bone loss in premenopausal women. J Rheumatol. 2005;32:1020–5.
63. Hämä lä inen H, Kaarela K, Krö ger H, et al. Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up. Joint Bone Spine. 2007;74:482–7. DOI: http://dx.doi.org/10.1016/j.jbspin.2007.01.021.
64. Gü ler-Yü ksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330–6. DOI: http://dx.doi.org/10.1136/ard.2007.086348.
65. Van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. 2013;24(4):1429–36. DOI: 10.1007/s00198-012-2073-z.
66. Tengstrand B, Larsson E, Klareskog L, Hafströ m I. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol. 2007;36(5):351–8. DOI: 10.1080/03009740701394021.
67. Habib GS, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol. 2005;24:129–33. DOI: http://dx.doi.org/10.1007/s10067-004- 0989-1.
68. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, et al. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum. 2001;44:1254–60. DOI: http://dx.doi.org/10.1002/1529-0131(200106)44:6%3C1254::AID-ART216%3E3.0.CO;2-G.
69. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18(6):683–90.
70. Oelzner P, Schwabe A, Lehmann G, et al. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int. 2008;28(11):1143–50. DOI: 10.1007/s00296-008-0576-x.
71. Van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12. DOI: http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00006.
72. Michel BA, Bloch DA, Fries JF. Predictors of fracture in early rheumatoid arthritis. J Rheumatol. 1991;18:804–8.
73. Nampei A, Hashimoto J. Clinical features of fracture with glucocorticoid induced osteoporosis and rheumatoid arthritis. Clin Calcium. 2006;16(11):1866–70.
74. Minaur NJ, Kounali D, Vedi S, et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford). 2002;41:741–9. DOI: 10.1093/rheumatology/41.7.741.
75. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997;24(8):1489–94.
76. Carbone LD, Kaeley G, McKown KM, et al. Effects of longterm administration of methotrexate on bone mineral density in rheumatoid arthritis. Calcif Tissue. 1999;64(2):100–1. DOI: http://dx.doi.org/10.1007/s002239900585.
77. Mazzantini M, Di Munno O, Incerti-Vecchi L, Pasero G. Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol. 2000;18(3):327–31.
78. Cranney AB, McKendry RJ, Wells GA, et al. The effect of low dose methotrexate on bone density. J Rheumatol. 2001;28(11):2395–9.
79. Urushibara M, Takayanagi H, Koga T, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 2004;50(3):794–804. DOI: http://dx.doi.org/10.1002/art.20206.
80. Kobayashi Y, Ueyama S, Arai Y, et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab. 2004;22(4):318–28. DOI: http://dx.doi.org/10.1007/s00774- 003-0489-4.
81. Di Munno O, Delle Sedie A, Rossini M, Adami S. Diseasemodifying antirheumatic drugs and bone mass in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(2):137–44.
82. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endrocrinol Metab. 2005;90(4):2456–65. DOI: http://dx.doi.org/10.1210/jc.2004-1978.
83. Cunningham J. Posttransplantation bone disease. Transplantation. 2005;79(6):629–34. DOI: http://dx.doi.org/10.1097/01.TP.0000149698.79739.EF.
84. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on the receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth cells. Biochem Biophys Res Commun. 2001;280(1):334–9. DOI: http://dx.doi.org/10.1006/bbrc.2000.4130.
85. Tengstrand B, Hafströ m I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol. 2002;29(11):2299–305.
86. Garton MJ, Reid DM. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis: effects of low-dose corticosteroids. Arthritis Rheum. 1993;36:222–8. DOI: http://dx.doi.org/10.1002/art.1780360213.
87. Mateo L, Nolla JM, Bonnin MR, et al. Sex hormone status and bone mineral density in men with rheumatoid arthritis. J Rheumatol. 1995;22(8):1455–60.
88. Stafford L, Bleasel J, Giles A, Handelsman D. Androgen deficiency and bone mineral density in men with rheumatoid arthritis. J Rheumatol. 2000;27(12):2786–90.
89. Haugeberg G, Uhlig T, Falch JA, et al. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninetyfour patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum. 2000;43:2776–84. DOI: http://dx.doi.org/10.1002/1529-0131(200012)43:12%3C2776::AID-ANR18%3E3.0.CO;2-N.
90. Nolla JM, Roig-Vilaseca D, Gomez-Vaquero C, et al. Frequency of osteoporosis in 187 men with rheumatoid arthritis followed in a university hospital. J Rheumatol. 2006;33(8):1472–5.
91. Hooyman J, Melton L, Nelson A, et al. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984;27:1353–61. DOI: http://dx.doi.org/10.1002/art.1780271205.
92. Reid IR. Relationships among body mass, its components, and bone. Bone. 2002;31:547–55. DOI: http://dx.doi.org/10.1016/S8756-3282(02)00864-5.
93. Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab. 1993;77:683–6.
94. Douchi T, Yamamoto S, Oki T, et al. Difference in the effect of adiposity on bone density between pre- and postmenopausal women. Maturitas. 2000;34:261–6. DOI: http://dx.doi.org/10.1016/S0378-5122(99)00114-0.
95. Filip R, Raszewski G. Bone mineral density and bone turnover in relation to serum leptin, alpha-ketoglutarate and sex steroids in overweight and obese postmenopausal women. Clinical Endocrinol (Oxford). 2009;70:214–20. DOI: http://dx.doi.org/10.1111/j.1365-2265.2008.03313.x.
96. Kim KC, Shin DH, Lee SY, et al. Relation between obesity and bone mineral density and vertebral fractures in korean postmenopausal women. Yonsei Med J. 2010;51(6):857–63. DOI: 10.3349/ymj.2010.51.6.857.
97. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175(2):405–15. DOI: http://dx.doi.org/10.1677/joe.0.1750405.
98. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21(10):1648–56. DOI: http://dx.doi.org/10.1359/jbmr.060707.
99. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309(1):99–109. DOI: http://dx.doi.org/10.1016/j.yexcr.2005.05.021.
100. Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73–8. DOI: http://dx.doi.org/10.1016/S0167- 0115(00)00152-X.
101. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17(2):200–9. DOI: http://dx.doi.org/10.1359/jbmr.2002.17.2.200.
102. Iwamoto I, Fujino T, Douchi T. The leptin receptor in human osteoblasts and the direct effect of leptin on bone metabolism. Gynecol Endocrinol. 2004;19:97–104. DOI: http://dx.doi.org/10.1080/09513590412331284389.
103. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825–36. DOI: http://dx.doi.org/10.1002/jcb.10156.
104. Scottich Intercollegiate Guidelines Network (SIGN) №71. Management of osteoporosis: a national clinical guideline. June 2003. Available from: www.sign.ac.uk
105. Krishnan E. Smoking, gender and rheumatoid arthritis-epidemiological clues to etiology. Results from the behavioral risk factor surveillance system. Joint Bone Spine. 2003;70(6):496–502. DOI: http://dx.doi.org/10.1016/S1297-319X(03)00141-6.
106. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(3):265–72. DOI: http://dx.doi.org/10.1186/ar578.
107. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62(9):835–41. DOI: http://dx.doi.org/10.1136/ard.62.9.835.
108. Goodson NJ, Silman AJ, Pattison DJ, et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford). 2004;43(6):731–6. DOI: http://dx.doi.org/10.1093/rheumatology/keh161.
109. Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 1997;40(11):1955–61. DOI: http://dx.doi.org/10.1002/art.1780401106.
110. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69(1):70–81. DOI: 10.1136/ard.2008.096487.
111. Eadington DW, Patrick AW, Frier BM. Association between connective tissue changes and smoking habit in type 2 diabetes and in non-diabetic humans. Diabetes Res Clin Pract. 1991;11(2):121–5. DOI: http://dx.doi.org/10.1016/0168-8227(91)90101-I.
112. Mattey DL, Hutchinson D, Dawes PT, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum. 2002;46(3):640–6. DOI: http://dx.doi.org/10.1002/art.10174.
113. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990;162(2):502–14. DOI: http://dx.doi.org/10.1016/0002- 9378(90)90420-C.
114. Michnovicz JJ, Hershcopf RJ, Naganuma H, et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N Engl J Med. 1986;315(21):1305–9. DOI: http://dx.doi.org/10.1056/NEJM198611203152101.
115. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001;68(5):259–70. DOI: http://dx.doi.org/10.1007/BF02390832.
116. Kirschbaum C, Wust S, Strasburger CJ. «Normal» cigarette smoking increases free cortisol in habitual smokers. Life Sci. 1992;50(6):435–42. DOI: http://dx.doi.org/10.1016/0024- 3205(92)90378-3.
117. Need AG, Kemp A, Giles N, et al. Relationships between intestinal calcium absorption, serum vitamin D metabolites and smoking in postmenopausal women. Osteoporos Int. 2002;13(1):83–8. DOI: http://dx.doi.org/10.1007/s198-002-8342-9.
118. Institute for Clinical Systems Improvement (ICSI) Health Care Guideline: Diagnosis and Treatment of steoporosis, 5th ed, July 2006.
119. Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737–45. DOI: http://dx.doi.org/10.1177/0961203306069344.
120. Lee S, Lee SY, Yoo WH. Association of apolipoprotein E polymorphism with bone mineral density in postmenopausal women with rheumatoid arthritis. Rheumatology (Oxford). 2005;44(8):1067–8. DOI: http://dx.doi.org/10.1093/rheumatology/keh675.
121. Chen J, Liu W, Lin Q, et al. Vitamin D deficiency and low bone mineral density in native Chinese rheumatoid arthritis patients.Int J Rheum Dis. 2014 Jan;17(1):66–70. DOI: 10.1111/1756- 185X.12160.
Рецензия
Для цитирования:
Таскина Е.А., Алексеева Л.И. Факторы риска развития остеопороза у больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(5):562-571. https://doi.org/10.14412/1995-4484-2014-562-571
For citation:
Taskina E.A., Alekseeva L.I. RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2014;52(5):562-571. (In Russ.) https://doi.org/10.14412/1995-4484-2014-562-571
Просмотров: 968
Послать статью по эл. почте 